Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device



Status:Completed
Conditions:Ocular
Therapuetic Areas:Ophthalmology
Healthy:No
Age Range:Any
Updated:2/17/2019
Start Date:June 2015
End Date:February 12, 2019

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The investigators would like to know if different imaging devices can improve the quality of
images and visualization of imaged tissues. Also, the investigators would like to find out
whether these changes are useful in the diagnosis and treatment of eye diseases. Using images
of previous participants will allow us to demonstrate the advancement of different
technologies, as well be used to allow comparisons between current technologies.

To test the quality of images from the Nidek MP-3 device and to measure Geographic Atrophy
(GA) in patients with Age-related Macular Degeneration (AMD).

Inclusion Criteria:

- Normal, healthy participants and patients with AMD

Exclusion Criteria:

1. Those suffering from head, neck or other injury which makes them unable to position
themselves in head restraint for imaging

2. Participants who are unable to maintain retinal fixation on a specified target

3. Participants unable to achieve sufficient pupil dilation and alignment stability for
imaging to take place

4. Patients with media opacity which preclude high quality imaging will be excluded.

5. Exclusion criteria include vulnerable patients; patients under 18, pregnant,
economically and educationally disadvantaged, decision impaired, or homeless people.
We exclude pregnant women because pregnancy often can alter eye anatomy.
We found this trial at
1
site
Doheny Eye Centers UCLA
Pasadena, California 91105
Phone: 323-442-6541
?
mi
from
Pasadena, CA
Click here to add this to my saved trials